{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Perez-Stable C"],"funding":["BLRD VA","Veterans Affairs","NCI NIH HHS","Bankhead-Coley Cancer Research Program, State of Florida","NIH HHS"],"pagination":["2442"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12561735"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13(10)"],"pubmed_abstract":["<b>Background/Objective:</b> Proteotoxic stress induced by inhibitors of the ubiquitin-proteasome system has been successful in multiple myeloma but not in solid cancers such as prostate cancer. Our objective is to find a combination with proteasome inhibitors that increases apoptotic cell death in all types of prostate cancer without harming non-cancer cells. <b>Methods:</b> The effectiveness of rencofilstat, a pan-cyclophilin inhibitor, combined with the ixazomib proteasome inhibitor, was investigated in multiple prostate cancer and non-cancer cells. Inducible knockdown of stress response XBP1s and cyclophilins A/B and inducible expression of XBP1s and cyclophilin B were developed in prostate cancer to determine functional roles. <b>Results:</b> Rencofilstat + ixazomib increased apoptoti"],"journal":["Biomedicines"],"pubmed_title":["Cyclophilin Inhibitor Rencofilstat Combined with Proteasome Inhibitor Ixazomib Increases Proteotoxic Cell Death in Advanced Prostate Cancer Cells with Minimal Effects on Non-Cancer Cells."],"pmcid":["PMC12561735"],"funding_grant_id":["1R03CA245780-22","R03 CA245780","I01-BX005051","8BC11","I01 BX005051"],"pubmed_authors":["Foster RT","Ure DR","Perez-Stable C","de Las Pozas A","Wangpaichitr M"],"additional_accession":[]},"is_claimable":false,"name":"Cyclophilin Inhibitor Rencofilstat Combined with Proteasome Inhibitor Ixazomib Increases Proteotoxic Cell Death in Advanced Prostate Cancer Cells with Minimal Effects on Non-Cancer Cells.","description":"<b>Background/Objective:</b> Proteotoxic stress induced by inhibitors of the ubiquitin-proteasome system has been successful in multiple myeloma but not in solid cancers such as prostate cancer. Our objective is to find a combination with proteasome inhibitors that increases apoptotic cell death in all types of prostate cancer without harming non-cancer cells. <b>Methods:</b> The effectiveness of rencofilstat, a pan-cyclophilin inhibitor, combined with the ixazomib proteasome inhibitor, was investigated in multiple prostate cancer and non-cancer cells. Inducible knockdown of stress response XBP1s and cyclophilins A/B and inducible expression of XBP1s and cyclophilin B were developed in prostate cancer to determine functional roles. <b>Results:</b> Rencofilstat + ixazomib increased apoptoti","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-04T03:07:13.383Z","creation":"2026-06-04T03:05:48.491Z"},"accession":"S-EPMC12561735","cross_references":{"pubmed":["41153724"],"doi":["10.3390/biomedicines13102442"]}}